
WHAT IS CLAIMED IS:

1. A composition for topical application of methylphenidate, comprising methylphenidate and a pharmaceutically acceptable adhesive in a flexible, finite system, wherein said composition delivers methylphenidate in an amount and rate sufficient to increase the methylphenidate plasma concentration of a subject being treated over a period of about 6-16 hours, followed by a steady decrease in the plasma concentration of methylphenidate.


- 2. The composition according to claim 1, wherein said increase in said methylphenidate plasma concentration is followed by a steady decrease in the plasma concentration of methylphenidate over a period of at least about 8 hours.
- 3. The composition according to claim 1, wherein said increase in said methylphenidate plasma concentration occurs over a period of about 6-12 hours.
- 4. The composition according to claim 1, wherein said increase in said methylphenidate plasma concentration is in the range of 0.06 (ng/mL)/hour to 6.0 (ng/mL)/hour.
- 5. The composition according to claim 1, wherein said increase in said methylphenidate plasma concentration is in the range of 0.4 (ng/mL)/hour to 2.5 (ng/mL)/hour.
- 6. The composition according to 1, wherein said composition comprises no more than about 5% weight/weight of acid functional monomers.
- 7. The composition according to claim1, wherein said composition is substantially free of ritalinic acid at the time of manufacture.



- The composition according to claim 1, wherein said composition 9. delivers a therapeutically effective amount over a period of time of about 12 to about 18 hours.
- 10. The composition according to claim 1, wherein the methylphenidate is delivered at a rate of about at least 5 mg per 24 hours.
- 11. A composition for topical application of methylphenidate, comprising methylphenidate and a pharmaceutically acceptable adhesive in a flexible, finite system,
- (i) wherein said composition comprises about 10 to 30 wt% methylphenidate, about 30 to 50 wt% acrylic adhesive, and about 30 to 50 wt% silicone adhesive and
- (ii) wherein said composition delivers methylphenidate in an amount and rate sufficient to increase the methylphenidate plasma concentration of a subject being treated over a period of about 6-16 hours, followed by a steady decrease in the plasma concentration of methylphenidate.
- 12. The composition according to claim 11, wherein said increase in said plasma concentration over about 6-16 hours is followed by a steady decrease in the plasma concentration of methylphenidate over a period of at least about 8 hours.
- 13. The composition according to claim 11, wherein said increase in said methylphenidate plasma concentration occurs over a period of about 6-12 hours.

- 14. The composition according to claim 11 wherein said increase in said methylphenidate plasma concentration is in the range of 0.06 (ng/mL)/hour to 6.0 (ng/mL)/hour.
- 15. The composition according to claim 11, wherein said composition comprises no more than about 5% weight/weight of acid functional monomers.
- 16. The composition according to claim 11, wherein said composition is substantially free of ritalinic acid at the time of manufacture.
- 17. The composition according to claim 11, wherein said composition delivers a therapeutically effective amount over a period of time of about 12 to about 24 hours.
- 18. The composition according to claim 11, wherein said composition delivers a therapeutically effective amount over a period of time of about 12 to about 18 hours.
- 19. The composition according to claim 11, wherein the methylphenidate is delivered at a rate of about at least 5 mg per 24 hours.
- 20. A method of treating attention deficit disorder and attention deficit/hyperactivity disorder comprising topically administering a composition of methylphenidate and a pharmaceutically acceptable adhesive in a flexible, finite system, wherein said composition delivers methylphenidate in an amount and rate sufficient to increase the methylphenidate plasma concentration of a subject being treated over a period of about 6-16 hours, followed by a steady decrease in the plasma concentration of methylphenidate.

The Contract




- 22. The method according to claim 20, wherein said increase in said methylphenidate plasma concentration is in the range of 0.06 (ng/mL)/hour to 6.0 (ng/mL)/hour.
- 23. The method according to claim 20, wherein said increase in said methylphenidate plasma concentration is in the range of 0.4 (ng/mL)/hour to 2.5 (ng/mL)/hour.
- 24. The method according to claim 20, wherein said composition comprises no more than about 5% weight/weight of acid functional monomers.
- 25. The method according to claim 20, wherein said composition is substantially free of ritalinic acid at the time of manufacture.
- 26. The method according to claim 20, wherein said composition delivers a therapeutically effective amount over a period of time of about 12 to about 24 hours.
- 27. The method according to claim 20, wherein said composition delivers a therapeutically effective amount over a period of time of about 12 to about 18 hours.
- 28. The method according to claim 20, wherein the methylphenidate is delivered at a rate of about at least 5 mg per 24 hours.
- 29. A method of treating attention deficit disorder and attention deficit/hyperactivity disorder comprising topically administering a



Atty. Dkt. No.: 041457-0630

composition of methylphenidate, and a pharmaceutically acceptable adhesive in a flexible, finite system,

- (i) wherein said composition comprises about 10 to 30 wt% methylphenidate, about 30 to 50 wt% acrylic adhesive, and about 30 to 50 wt% silicone adhesive and
- (ii) wherein said composition delivers methylphenidate in an amount and rate sufficient to increase the methylphenidate plasma concentration of a subject being treated over a period of about 6-16 hours, followed by a steady decrease in the plasma concentration of methylphenidate.
- 30. The method according to claim 29, wherein the increasing plasma concentration over about 6-16 hours is followed by a steady decrease in the plasma concentration of methylphenidate over a period of at least about 8 hours.
- 31. The method according to claim 29, wherein said increase in said methylphenidate plasma concentration occurs over a period of about 6-12 hours.
- 32. The method according to claim 29, wherein said increasing plasma concentration is in the range of 0.06 (ng/mL)/hour to 6.0 (ng/mL)/hour.
- 33. The method according to claim 29, wherein said composition comprises no more than about 5% weight/weight of acid functional monomers.
- 34. The method according to claim 29, wherein said composition is substantially free of ritalinic acid at the time of manufacture.



- 36. The method according to claim 29, wherein wherein said composition delivers a therapeutically effective amount over a period of time of about 12 to about 18 hours.
- The method according to claim 29, wherein the methylphenidate is 37. delivered at a rate of about at least 5 mg per 24 hours.
- The method according to claim 20, wherein said increase in said 38. methylphenidate plasma concentration occurs over a period of about 6-12 hours.